Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •1. The diagnosis was non-plaque psoriasis.
• •2. Subjects with concurrent skin diseases that the investigator believes would interfere with the study assessments.
• •3. Presence of infection or immune-related disease.
• •4. Subjects with a history of TB or at risk for TB.
• •5. Received related treatment within the time window specified in the protocol.
• •6. An interval of less than 5 half-lives or 28 days (if any available half-life data) from the last dose of a strong CYP1A2/CYP3A4 inhibitor or inducer, or a plan to use concurrently medications with strong CYP1A2/CYP3A4 inhibitory or inductive effect during study participation.
• •7. The investigator has determined that there are clinically significant test results and that participation in this trial would pose an unacceptable risk to patients; Or the laboratory values of the subjects in the screening period meet the criteria specified in the protocol.
• •8. Pregnant or lactating women, or women who plan to become pregnant during study participation.
• •9. A history of severe drug allergies.
• •10. Any other conditions in which the investigator considers it unsuitable for the subject to participate in this study.